Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 203 for melanoma

Edit search filters
  1. A Study of the Combination of IMCgp100 with Durvalumab and/or Tremelimumab for Patients with Advanced Cutaneous Melanoma

  2. A Study to Evaluate Ipilimumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ DEVICE with IV-administered Nivolumab in Patients with Metastatic Melanoma

    Rochester, MN

  3. A Study to Evaluate Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced Melanoma

    Rochester, MN

  4. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

  5. Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

    Rochester, MN

  6. A Study to Evaluate UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

    Scottsdale/Phoenix, AZ

  7. Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)

  8. A Study to Evaluate Radiation Therapy, Plasma Exchange, and Immunotherapy in Melanoma

    Rochester, MN

  9. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects

    Scottsdale/Phoenix, AZ

  10. A Study to Evaluate the Safety and Effectiveness of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma Patients

    Rochester, MN, Jacksonville, FL

.

Mayo Clinic Footer